XML 32 R23.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Information | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Segment Information | 15. Segment information The Company operates and manages its business as a single reporting and operating segment, which is the research and development of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The Company's CODM is the Chief Executive Officer and Chief Financial Officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is reported on the consolidated statement of operations and comprehensive loss. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to deploy these resources across functions and programs that are in line with the Company's long-term company-wide strategic goals. The following table presents reportable segment net loss, including significant expense categories, attributable to the Company's reportable segment for the three and six months ended June 30, 2025 and 2024.
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | (in thousands) |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreements |  | $ | 250 |  |  | $ | 1,073 |  |  | $ | 250 |  |  | $ | 53,477 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Discovery costs |  |  |  |  |  |  |  |  |  |  |  |
Direct external costs |  |  | 259 |  |  |  | 1,398 |  |  |  | 957 |  |  |  | 3,124 |
Laboratory supplies and research materials |  |  | 90 |  |  |  | 959 |  |  |  | 344 |  |  |  | 1,957 |
Personnel related costs |  |  | 243 |  |  |  | 3,232 |  |  |  | 1,750 |  |  |  | 6,418 |
Facilities related costs |  |  | 145 |  |  |  | 393 |  |  |  | 503 |  |  |  | 798 |
Other costs |  |  | 65 |  |  |  | 842 |  |  |  | 643 |  |  |  | 1,754 |
Development costs |  |  |  |  |  |  |  |  |  |  |  |
Direct external costs |  |  |  |  |  |  |  |  |  |  |  |
Camonsertib program |  |  | 1,848 |  |  |  | 3,961 |  |  |  | 4,114 |  |  |  | 7,941 |
Lunresertib program |  |  | 3,999 |  |  |  | 7,660 |  |  |  | 8,274 |  |  |  | 15,767 |
RP-1664 program |  |  | 1,579 |  |  |  | 1,412 |  |  |  | 2,921 |  |  |  | 3,008 |
RP-3467 and Polθ program |  |  | 1,541 |  |  |  | 773 |  |  |  | 2,638 |  |  |  | 2,328 |
Personnel related costs |  |  | 5,070 |  |  |  | 9,186 |  |  |  | 13,233 |  |  |  | 18,845 |
Facilities related costs |  |  | 233 |  |  |  | 213 |  |  |  | 480 |  |  |  | 421 |
Other costs |  |  | 695 |  |  |  | 1,186 |  |  |  | 1,584 |  |  |  | 2,618 |
Debiopharm development cost reimbursement |  |  | (1,413 | ) |  |  | (880 | ) |  |  | (2,682 | ) |  |  | (1,380 | )
R&D tax credits |  |  | (71 | ) |  |  | (260 | ) |  |  | (206 | ) |  |  | (554 | )
Total research and development costs |  | $ | 14,283 |  |  | $ | 30,075 |  |  | $ | 34,553 |  |  | $ | 63,045 |
Personnel related costs |  |  | 2,944 |  |  |  | 5,220 |  |  |  | 7,522 |  |  |  | 10,939 |
Other general administrative costs (1) |  |  | 3,085 |  |  |  | 3,097 |  |  |  | 6,159 |  |  |  | 5,996 |
Total general and administrative costs |  | $ | 6,029 |  |  | $ | 8,317 |  |  | $ | 13,681 |  |  | $ | 16,935 |
Restructuring costs |  |  | 3,384 |  |  |  | — |  |  |  | 6,649 |  |  |  | — |
Total operating expenses |  | $ | 23,696 |  |  | $ | 38,392 |  |  | $ | 54,883 |  |  | $ | 79,980 |
Gain on sale of technology and other assets |  |  | 5,666 |  |  |  | — |  |  |  | 5,666 |  |  |  | — |
Loss from operations |  | $ | (17,780 | ) |  | $ | (37,319 | ) |  | $ | (48,967 | ) |  | $ | (26,503 | )
Other income, net (2) |  |  | 1,284 |  |  |  | 2,871 |  |  |  | 2,798 |  |  |  | 5,846 |
Income tax expense |  |  | (248 | ) |  |  | (326 | ) |  |  | (618 | ) |  |  | (955 | )
Net loss |  | $ | (16,744 | ) |  | $ | (34,774 | ) |  | $ | (46,787 | ) |  | $ | (21,612 | )
(1) Includes professional fees, directors and officers insurance costs, public company operating costs, information technology related costs, and other administrative costs. (2) Includes interest income and other expenses. The following presents segment revenue and long lived assets by geographic location, along with major collaborator information. Revenue by location is as follows:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | (in thousands) |
United States |  | $ | 250 |  |  | $ | — |  |  | $ | 250 |  |  | $ | 2,589 |
Switzerland |  |  | — |  |  |  | 1,073 |  |  |  | — |  |  |  | 50,888 |
Total revenue |  | $ | 250 |  |  | $ | 1,073 |  |  | $ | 250 |  |  | $ | 53,477 |
The Company’s property and equipment, net by country of domicile (Canada) and its subsidiary in the United States are as follows:
|  | As of June 30, |  |  | As of December 31, |
|  | 2025 |  |  | 2024 |
|  | (in thousands) |
Canada |  | $ | — |  |  | $ | 2,143 |
United States |  |  | 72 |  |  |  | 151 |
Total property and equipment, net |  | $ | 72 |  |  | $ | 2,294 |
The Company’s right-of-use assets by country of domicile (Canada) and its subsidiary in the United States are as follows:
|  | As of June 30, |  |  | As of December 31, |
|  | 2025 |  |  | 2024 |
|  | (in thousands) |
Canada |  | $ | 58 |  |  | $ | 891 |
United States |  |  | 571 |  |  |  | 1,033 |
Total right-of-use assets, net |  | $ | 629 |  |  | $ | 1,924 |
Major Customers The Company had one customer (a major collaborator) that represents more than 10% of total revenue in each of the three and six months ended June 30, 2025. The amount of revenue derived from this customer for the three and six months ended June 30, 2025 was $0.3 million. A different customer (another major collaborator) represented more than 10% of total revenue in each of the three and six months ended June 30, 2024. The amount of revenue derived from this customer for the three and six months ended June 30, 2024 was $1.1 million and $50.9 million, respectively.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration